ESRD Risk Small Among Type 2 Diabetics

Share this content:
Type 2 diabetes is among the leading causes of end-stage renal disease (ESRD), but the estimated cumulative risk of ESRD at 20 years after diagnosis of type 2 diabetes is less than 1%.
Type 2 diabetes is among the leading causes of end-stage renal disease (ESRD), but the estimated cumulative risk of ESRD at 20 years after diagnosis of type 2 diabetes is less than 1%.

Type 2 diabetes is among the leading causes of end-stage renal disease (ESRD), but the risk of ESRD developing in individuals with type 2 diabetes is small, investigators concluded in a presentation at the 55th European Renal Association-European Dialysis and Transplant Association congress in Copenhagen, Denmark.

In a Finnish study of 421,429 patients diagnosed with type 2 diabetes from 1990 to 2011, 1516 developed ESRD and 150,524 died before the end of 2013. The estimated cumulative risk of ESRD was 0.29% at 10 years and 0.74% at 20 years from the diagnosis of type 2 diabetes, Patrik Finne, MD, PhD, of Helsinki University Hospital, and colleagues reported in a study abstract. Male patients had a nearly 2-fold higher risk of ESRD than female patients.

Patients diagnosed with type 2 diabetes during 2000 to 2011 had a 28% lower risk of ESRD than those diagnosed during 1990 to 1994.

Investigators defined ESRD as the start of renal replacement therapy. They estimated the cumulative risk of ESRD using methods that take death into account as a competing risk event.

“Although type 2 diabetes is a very common cause of ESRD among patients who enter renal replacement therapy, type 2 diabetes patients' risk of developing ESRD is small especially when compared to their risk of dying without ESRD,” the authors concluded.

Reference

Finne P, Groop PH, Arffman M, et al. Risk of developing end-stage renal disease after diagnosis of type 2 diabetes. Data presented at the 55th European Renal Association-European Dialysis and Transplant Association congress in Copenhagen, Denmark, May 24–27. Abstract SP300.


You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters